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Pediatric craniophar-
yngiomas are effectively
treated with radiation, but no
studies exist comparing out-
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reviewed the outcomes for
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tion therapy (IMRT) for pediatric craniopharyngioma in terms of disease control, cyst
dynamics, and toxicity.
Methods and Materials: We reviewed records from 52 children treated with PBT
(nZ21) or IMRT (nZ31) at 2 institutions from 1996-2012. Endpoints were overall
survival (OS), disease control, cyst dynamics, and toxicity.
Results: At 59.6 months’ median follow-up (PBT 33 mo vs IMRT 106 mo; P<.001),
the 3-year outcomes were 96% for OS, 95% for nodular failure-free survival and 76%
for cystic failure-free survival. Neither OS nor disease control differed between treat-
ment groups (OS PZ.742; nodular failure-free survival PZ.546; cystic failure-free
survival PZ.994). During therapy, 40% of patients had cyst growth (20% requiring
intervention); immediately after therapy, 17 patients (33%) had cyst growth (transient
in 14), more commonly in the IMRT group (42% vs 19% PBT; PZ.082); and 27%
experienced late cyst growth (32% IMRT, 19% PBT; PZ.353), with intervention
required in 40%. Toxicity did not differ between groups. On multivariate analysis, cystMD, PhD, Department of
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changes were common dur-
ing and after treatment, and
close follow-up is needed to
prevent unnecessary
interventions.growth was related to visual and hypothalamic toxicity (PZ.009 and .04, respec-
tively). Patients given radiation as salvage therapy (for recurrence) rather than adju-
vant therapy had higher rates of visual and endocrine (PZ.017 and .024,
respectively) dysfunction.
Conclusions: Survival and disease-control outcomes were equivalent for PBT and
IMRT. Cyst growth is common, unpredictable, and should be followed during and after
therapy, because it contributes to late toxicity. Delaying radiation therapy until recur-
rence may result in worse visual and endocrine function.  2014 Elsevier Inc.Introduction
Craniopharyngiomas arise in the suprasellar region. Despite
their noninfiltrative growth pattern, their dense adherence to
and compression of nearby critical structures make treat-
ment difficult (1, 2). Numerous reports during the past few
decades suggest that subtotal resection followed by radia-
tion therapy (RT) produces outcomes superior to those of
aggressive surgery alone (3e16). Contemporary strategies
hence favor maximal safe resection, to limit potential sur-
gical morbidity, followed by adjuvant RT. However, con-
cerns regarding radiation-induced toxicities, including
vascular changes, cognitive deficiencies, and secondary
malignancies, persist.
Many published findings on outcome and toxicity after
RT involve the use of relatively old RT techniques. Tech-
nologic improvements in imaging and in radiation planning
and delivery have improved the conformality of radiation
doses to target volumes and reduced the doses to nearby
normal tissues. The current standard of care at many
treatment centers is photon-based intensity modulated ra-
diation therapy (IMRT); however, the superior dose profiles
provided by proton beam therapy (PBT) have prompted the
increased use of PBT where available.
A challenging component of craniopharyngioma man-
agement is the potential for cystic growth during or after
RT. As radiation becomes more conformal and the use of
particle therapy (eg, PBT) becomes more prevalent,
monitoring and accounting for cyst changes during treat-
ment are essential to avoid underdosing target structures or
overdosing critical structures (17e23). Furthermore, cystic
components of craniopharyngiomas can also change after
RT is completed. However, both the incidence and impli-
cations of such changes are unclear and complicate the
evaluation of treatment response (24, 25). Significant
expansion of cysts after treatment may compress critical
structures, necessitating additional invasive procedures.
Transient asymptomatic enlargement, however, may reflect
only a response to treatment, as has been noted for other
high- and low-grade tumors. In such cases, additional
procedures may be unnecessary and could impart additional
treatment-related morbidity (6, 7).
To clarify these issues, we evaluated a large group of
pediatric patients with craniopharyngioma treated at 2
institutions with modern RT techniques to compareoutcomes, cyst dynamics, and late toxicity after IMRT
versus PBT.
Methods and Materials
Patients
Eligible patients were identified from institutional data-
bases at The University of Texas MD Anderson Cancer
Center and Methodist Hospital (both in Houston, TX) after
permission was obtained from the respective institutional
review boards. Inclusion criteria were (1) histologic
confirmation of craniopharyngioma; (2) patient age
18 years at time of RT; and (3) treatment with IMRT or
PBT from 1996 through 2012. Once PBT was available, it
was used to treat all pediatric craniopharyngioma patients
between 2007 and 2012.
Patient characteristics extracted from the records
included age at time of RT, demographics, tumor size at
diagnosis, and presenting symptoms (visual deficits, hy-
drocephalus, endocrine deficiencies). Surgical intervention
variables captured included date of first surgery, extent of
resection, number of surgeries, and surgical complications.
Radiation treatment was considered definitive (if only
biopsy or cyst drainage had been done previously), post-
operative/adjuvant (after either a subtotal resection [STR]
or a gross total resection [GTR]), or salvage (for disease
that recurred after previous interventions). Radiation dose,
fractionation, and modality (IMRT vs PBT) were noted.
The number of interval scans obtained during RT (to
monitor cyst size and ensure adequate target coverage) was
recorded as well.
Disease progression was further categorized as growth
of the solid, nodular disease component versus cystic
changes, the latter recorded as (1) occurring during RT;
(2) early cyst enlargement (3 months after RT); and
(3) late cyst growth (>3 months after RT). The date of first
progression of nodular versus cystic growth was based on
serial magnetic resonance imaging.
Findings on late toxicity were extracted from multidis-
ciplinary clinical evaluations, laboratory values, and imag-
ing. Changes in symptoms were recorded as being before
treatment versus after surgery versus late (after RT). Endo-
crinopathies were defined as deficiencies requiring supple-
mentary medication and confirmed by laboratory screening.
Table 1 Patient, disease, and treatment characteristics by treatment group (nZ52)
Variable All patients
Treatment groups
PPBT IMRT
Follow-up time (mo)
Median 59.6 33.1 106.1 <.001
Range 4.7-185.3 10.5-65.6 8.9-185.3
Age (y), median 8.9 9.1 8.8 1.00
Tumor size (cm), median 3.8 4.5 3.6 .19
Sex
Male 23 (44) 9 (43) 14 (45) 1.00
Female 29 (56) 12 (57) 17 (55)
Ethnicity
Asian 1 (2) 1 (5) 0 .540
African American 13 (25) 4 (19) 9 (29)
Hispanic 19 (37) 9 (43) 10 (32)
Caucasian 19 (37) 7 (33) 12 (39)
Presenting symptoms
Headaches 31 (60) 16 (76) 15 (48) .038
Visual defects 36 (69) 11 (52) 25 (81) .083
Endocrinopathies 16 (31) 4 (19) 12 (39) .22
Extent of first surgery
Other* 26 (50) 7 (33) 19 (61) .032
Subtotal resection 20 (38) 9 (43) 11 (35)
Gross total resection 6 (12) 5 (24) 1 (3)
No. of surgeries
1 32 (62) 15 (71) 17 (55) .749
2 13 (25) 4 (19) 9 (29)
3 6 (12) 2 (10) 4 (13)
4 1 (2) 0 1 (3)
Radiation dose, median 50.4 Gy 50.4 Gy (RBE) 50.4 Gy
Radiation intent
Postoperative 23 (44) 8 (38) 15 (48) .586
Definitive 7 (13) 4 (19) 3 (10)
Salvage 22 (42) 9 (43) 13 (42)
Reimaging during RT
None 28 (54) 2 (10) 26 (84)
1 4 (8) 4 (19) 0
2 10 (19) 7 (33) 3 (10)
3 3 (6) 3 (14) 0
Weekly 7 (13) 5 (24) 2 (6)
Cyst change during RT
Growth 10 (19) 6 (29) 4 (13)
Contraction 6 (12) 6 (29) 0
No change 8 (15) 8 (37) 0
Unknown 28 (54) 1 (5) 27 (87)
Treatment change during RT
due to cyst growth
Yes 5 (10) 2 (10) 3 (10)
No 20 (38) 17 (81) 3 (10)
N/A 27 (52) 2 (10) 25 (81)
Cyst growth 3 mo after RT
Yes 17 (33) 4 (19) 13 (42) .082
No 34 (65) 17 (81) 17 (55)
Unknown 1 (2) 0 1 (3)
Cyst growth >3 mo after RT
Yes 14 (27) 4 (19) 10 (32) .353
(continued on next page)
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Table 1 (continued )
Variable All patients
Treatment groups
PPBT IMRT
No 38 (73) 17 (81) 21 (68)
Cyst growth after RT requiring intervention
Yes 6 (12) 3 (14) 3 (10)
No 46 (88) 18 (86) 28 (90)
Abbreviations: IMRT Z intensity modulated radiation therapy; PBT Z proton beam therapy; RT Z radiation therapy.
Values are number (percentage) unless otherwise noted.
* Cyst drainage, fenestration, shunting.
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as a deficiency of >3 anterior pituitary hormones. Any de-
viation in baseline vision (field cuts or acuity) on physical
and ophthalmologic examination was recorded as a visual
change. Because formal neurocognitive testing was not ob-
tained on all patients, data concerning cognitive toxicity
could not be retrospectively extracted. Vascular toxicities,
including moyamoya, stroke, and vessel malformations,
were identified on cranial imaging. Hypothalamic obesity
was based on the primary clinician’s diagnosis of morbid or
hypothalamic obesity during follow-up.Statistical analysis
Descriptive statistics were used to evaluate baseline char-
acteristics, and categorical data were analyzed by using
Fisher’s exact test. Survival times were calculated from the
RT end date to the first occurrence of the considered event.
The Kaplan-Meier method was used to calculate overall
survival (OS) and cystic and nodular progression-free sur-
vival times. Log-rank tests were used to assess the equality
of the survival function across groups. A 2-sided 5% sig-
nificance level was used for analysis.
The Cox proportional hazard model was used for uni-
variate and multivariate analysis to assess the effect of
patient, tumor, and other factors on the endpoints. Multi-
variate assessment was done by backwards elimination,
with all factors found to have a P value of .25 on uni-
variate analysis included in the assessment. Estimated
hazards are reported. The Wald test was used to assess the
influence of covariates on the model. Stata/MP v13.0
(College Station, TX) was used for data analysis.Results
Patient characteristics and tumor management
Fifty-two patients (21 treated with PBT and 31 with IMRT)
met the criteria for this analysis; patient, disease, and
treatment characteristics are summarized in Table 1.
Upfront surgical interventions varied. The first surgical
procedure was definitive in 26 patients (STR nZ20, GTRnZ6). Just over one-third of patients (nZ20) required
more than 1 surgical procedure before RT (Table 1).
Radiation therapy was delivered to doses of 50.4-54 Gy
at 1.8 Gy per fraction. Thirty-one children were treated
with IMRT, and 21 were treated with PBT (Table 1). Most
of the PBT was delivered with passive scatter techniques
(nZ18).
As expected, follow-up was shorter for the PBT group
(P<.001), because PBT was not available until 2006.
Otherwise, the groups were well balanced (Table 1).
Imaging during RT
Given the unpredictability of craniopharyngioma cyst dy-
namics, periodic imaging during RT ensures that the tumor
is covered adequately by the prescribed dose throughout the
entire treatment course. Only 44% of the patients among
the entire cohort (PBT nZ19, IMRT nZ5) had imaging
during RT; most of these patients had been treated before
the importance of interval imaging was reported (23). Of
those patients who did undergo surveillance imaging during
RT, 2 PBT-treated patients underwent MRI, whereas the
other 22 patients underwent CT imaging; 10 (19%) expe-
rienced documented cyst growth, with 5 requiring changes
in the treatment plan. Two patients required cyst decom-
pression (1 with anatomic changes after decompression that
required RT replanning), and the other 3 required adaptive
replanning (1 required 2 replans). Six children had docu-
mented cyst contraction during RT, which did not require
replanning. Four patients had improvement in visual
symptoms during RT, some related to cyst contraction.
No correlation was found between imaging during RT
and late cyst growth (PZ.764) or nodular progression
(PZ.493). Cyst growth during RTwas unrelated to late cyst
growth on univariate analysis (PZ.099).
Outcomes
With a median follow-up of 59.6 months for the entire
cohort (PBT 33 months vs IMRT 106 months; P<.001), the
3-year OS rate was 96%, and the median survival time was
not reached. Nodular recurrences of a solid tumor compo-
nent were considered distinct from cyst growth and
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(CFFS) and nodular failure-free survival (NFFS) rates for
the entire group were 75.5% and 95.0%, respectively.
No difference in OS was found between patients
treated with PBT or IMRT (3-year OS 94.1% PBT vs
96.8% IMRT; PZ.742) (Fig. 1). The 3-year CFFS and
NFFS rates were also similar between groups (CFFS
67.0% PBT and 76.8% IMRT; PZ.994), but more of the
IMRT group had late cystic growth (10-year CFFS rate
67.8%). One patient in each treatment group had nodular
failure (3-year NFFS rates 91.7% PBT vs 96.4% IMRT;
PZ.546); the patient treated with PBT had progression at
26 months and the patient with IMRT at 24 months. No
differences by RT intent (salvage vs definitive or adju-
vant) were observed in 3-year OS, CFFS, or NFFS rates
(PZ.294 OS, PZ.412 CFFS, and PZ.951 NFFS). To
assess the potential impact of shorter follow-up for pa-
tients treated with PBT, data points were censored at 3
years and data reanalyzed. This analysis confirmed there
was no statistical difference between PBT and IMRT for
any outcome measure.
Four of the 52 patients had died at the time of analysis: 1
from cyst progression after STR and adjuvant RT and the
other 3 from treatment-related morbidity (uncontrolled
diabetes insipidus and postoperative neurologic injury).C
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Fig. 1. Survival curves according to treatment.
(A) Overall survival; (B) nodular failure-free survival;
(C) cystic failure-free survival. Treatment modality (proton
beam therapy vs intensity modulated (photon) radiation
therapy [IMRT]) did not affect any of these survival
outcomes.Cyst dynamics after RT
Seventeen patients (33%) had imaging evidence of early
cyst growth (within 3 months of completing RT), with a
greater percentage occurring in the IMRT group (42% vs
19% PBT) (Table 1). This apparent difference was not
significant (PZ.082). Fourteen of the 17 patients with early
cyst growth had only transient enlargement that resolved on
follow-up imaging.
Fourteen patients (27%) had late cyst growth (>3
months after RT), with no difference between groups (32%
IMRT vs 19% PBT; PZ.353), and 6 patients required
additional intervention (3 cyst drainage, 2 catheter place-
ment, and 1 surgical fenestration) (Table 1).
The reasons why some patients had early or late cyst
growth and others did not are unclear. We hypothesized that
patients with low frequency or without surveillance imag-
ing may be at increased risk for posttreatment cyst growth
due to marginal misses from dynamic cyst enlargement
while on treatment. However, less frequent surveillance
imaging was not correlated with early cyst growth
(PZ.376). Similarly, late cyst growth was not impacted by
the use of surveillance imaging (PZ.764).
Univariate analysis of factors that influenced (or may
have been influenced by) persistent cyst growth (Table 2)
included hypothalamic obesity (hazard ratio [HR] 5.14,
PZ.004) and visual function (HR 5.68, PZ.004). On
multivariable analysis, however, only hypothalamic obesity
(HR 3.46, PZ.04) and visual function (HR 6.01, PZ.009)
retained significance (Table 2).Toxicity
The potential for long-term survival among patients with
this type of tumor underscores the importance of mini-
mizing treatment-related toxicity. In our study, >50% of
patients had some perioperative morbidity, with nearly 40%
Table 3 Disease- and treatment-related morbidity identified
after radiation
Variable All patients
Treatment groups
PPBT IMRT
Late morbidity*
Vascular 5 (10) 2 (10) 3 (10) 1.00
Vision 5 (10) 1 (5) 4 (13) .637
Hypothalamic obesity 13 (25) 4 (19) 9 (29) .523
Endocrinopathy 40 (77) 16 (76) 24 (77) 1.00
Panhypopituitarism 24 (46) 7 (33) 17 (55) .162
Othery 16 (31) 9 (43) 7 (23) .139
Abbreviations as in Table 1.
Values are number (percentage).
* Toxicities newly acquired from start of radiation.
y Growth hormone deficits, hypothyroidism, adrenal insufficiency,
sexual hormone deficiencies.
Table 2 Univariate and multivariate analysis of predictors
and morbidity of cyst growth
Variable
Hazard
ratio
95%
CI P
Univariate analysis
Sex 1.03 0.36-2.97 .957
Ethnicity
Hispanic 1.07 0.24-4.81 .929
Caucasian 2.24 0.65-7.68 .202
Age at RT 0.96 0.83-1.10 .553
RT treatment year 1.11 0.98-1.27 .103
RT modality (PBT vs IMRT) 1.00 0.29-3.46 .994
Reimaging during RT 2.88 0.83-9.98 .095
Cyst growth during RT 3.98 0.77-20.57 .099
RT intent (adjuvant/
definitive vs salvage)
0.62 0.21-1.88 .402
RT dose 1.00 1.00-1.01 .169
Early cyst growth (3 mo
after RT)
0.59 0.16-2.15 .425
Late panhypopituitarism 1.60 0.43-5.90 .483
Vascular toxicity 1.53 0.34-6.94 .578
Hypothalamic obesity 5.14 1.68-15.75 .004
Visual toxicity 5.68 1.74-18.61 .004
Multivariate analysis
RT treatment year 1.15 1.00-1.31 .043
Visual toxicity 6.01 1.55-23.30 .009
Hypothalamic obesity 3.46 1.06-11.30 .040
Abbreviation: CI Z confidence interval. Other abbreviations as in
Table 1.
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hypopituitarism (nZ10). The extent of surgery (GTR vs
STR vs other) before RT did not correlate with post-
operative endocrine (PZ.096) or visual (nZ11) (PZ.64)
complications. Patients who had more surgical procedures
before RT may have had more visual complications after
surgery, but this apparent difference was not statistically
significant (PZ.072).
Forty patients (77%) were found to have a least 1
additional endocrinopathy after RT, 24 (46%) of which
were new-onset panhypopituitarism. Of the other 16 pa-
tients, hypothyroidism (nZ7, 13%) and hypogonadism
(nZ4, 8%) were most common. Thirteen patients were
diagnosed with hypothalamic obesity (PBT nZ4, IMRT
nZ9; PZ.523). Two events were directly correlated with
surgical toxicity. The remaining 11 may have resulted from
surgery but were not diagnosed until after RT or alterna-
tively were due to the combined effects of surgery and RT.
Cranial imaging in 5 patients suggested vascular injury
(PBT nZ2, IMRT nZ3; PZ1.0): 3 had symptomatic
strokes, 1 had a radiologic vascular malformation, and 1
had radiologic moyamoya.
No differences in late RT toxicity were identified in
children treated with PBT versus IMRT (Table 3). In the 22
patients receiving RT as salvage therapy, there was signif-
icantly more morbidity related to visual (PZ.017) and
endocrine (PZ.024) dysfunction and a higher rate ofpanhypopituitarism (PZ.023) compared with patients who
received RT as definitive or adjuvant therapy.
Discussion
This study represents a multi-institutional evaluation of one
of the largest groups of pediatric patients with cranio-
pharyngioma treated with PBT to date, and is the only
comparison of such patients with patients treated with
modern, conformal photon-based IMRT.
As PBT becomes increasingly available worldwide,
clinical studies of its efficacy are important to validate
previous dosimetric evidence of its advantages over photon-
based therapy (20e22). Published 10-year survival rates
range from 83% to 91% and are consistent with our finding
of 86% (12, 17). Notably, however, no difference in OS was
observed between treatment groups (PZ.742). Equivalency
had been suggested by previous retrospective studies, but
until this study a comparison cohort was not available (18,
19, 26).
Considerable variability and ambiguity in disease pro-
gression definitions complicate comparisons between
studies. Of studies defining control as growth of the solid
component of the tumor, control rates range from 92% to
100% when fractionated RT is given after STR (13).
Alternatively, Merchant et al (17) defined progression as
growth of the solid portion or persistent cystic growth more
than 3 years after treatment; they reported similar control
rates (88-96%).
We considered solid and cystic growth separately,
because each may be associated with unique outcomes. Our
NFFS rates at 3 years (95%) were consistent with previous
reports (13, 17). Cyst growth is more challenging to control
(3-year CFFS rate 76%), but its biologic significance is
undefined. Importantly, there were no differences between
PBT and IMRT in 3-year nodular (PZ.546) or cystic
(PZ.994) outcomes.
Patterns of cystic change in craniopharyngiomas remain
underreported. Cyst growth has a significant impact on
Bishop et al. International Journal of Radiation Oncology  Biology  Physics360treatment planning. Frequent surveillance imaging during
treatment allows for tighter RT dose distribution because
cyst enlargement can be monitored. Our rate of intervention
prompted by cyst growth during RT was 20% among those
imaged, slightly less than previously reported (35%) but
still noteworthy (23). The influence of surveillance imaging
on long-term outcomes, however, is not fully understood.
We found no difference in CFFS between patients with and
without interval imaging (PZ.764).
Cyst growth seems to be of 2 types: early yet transient
growth and slowly progressive, late growth. One-third of
our patients experienced cyst growth immediately after RT,
and all but 3 cases subsequently resolved. Two other groups
reported similar observations, with rates of transient, early
cyst growth as high as 52% (24, 25). Interestingly, although
the cysts reached their maximum dimension in less than
2 months after RT, they took 10 months to contract (24).
Transient cyst expansion after RT is not unique to cranio-
pharyngiomas and has also been reported for pilocytic as-
trocytoma (27).
The high rate of early cyst growth after photon-based RT
(52%) reported by Shi et al (24) is similar to the IMRT
(photon)-treated group (42%). The similarity in early cyst
growth between these 2 photon-treated groups and the dif-
ference in regard to the proton group (19%) is notable
(PZ.082). Early cyst growth suggests that cysts do not
respond to RT in the same way as does the solid component;
the lag time for cysts to contract after RT is analogous to the
time needed for late tissue remodeling and vascular fibrosis.
Recognizing transient cyst growth is critical for sparing
patients unnecessary intervention. We recommend that if
there is asymptomatic, early cyst growth immediately after
RT, interventions should be avoided and the patients closely
monitored. The more challenging scenario is when cysts
persist and continue to grow. Although most late cyst
growth eventually stabilized in our group (57%), these
children experienced morbidity (visual outcomes and hy-
pothalamic obesity) from the cyst progression, which em-
phasizes the need for close observation and intervention for
continued cyst expansion.
Perioperative morbidity rates range from 8% to 14%,
with rates of diabetes insipidus after conservative surgery
of 33% and postoperative panhypopituitarism in the high
teens (5e8, 12, 14, 16, 28). Radiation also impacts
endocrine function. In our study, new endocrinopathies
after RT (77%) were consistent with other published rates
(85-95%) (15). However, we observed higher rates of
panhypopituitarism than recently reported (30%) (28),
suggesting this toxicity may be underreported in the
literature. Our study also shows that the rate of pan-
hypopituitarism continues to increase with time, as sug-
gested by the greater frequency observed in our IMRT
group owing to longer follow-up. Importantly, although
endocrine dysfunction is often attributed to RT, the loca-
tion of the tumor, unpredictable nature of cyst growth, and
surgical manipulation must also be considered as
contributing factors (8, 29).Hypothalamic obesity is a morbid treatment-related
toxicity. We observed a relatively low rate of obesity
attributable to hypothalamic dysfunction (25%) compared
with a recent report suggesting that only 25% of cranio-
pharyngioma patients maintained a normal body mass (30).
However, without prospectively collected data, under-
standing the interplay between hypothalamic obesity, other
endocrine deficiencies, socioeconomic influences, and
populational trends will remain difficult.
Neurocognitive and behavioral outcomes are also chal-
lenging to quantify retrospectively. Two previous reports
suggested that patients treated for craniopharyngioma did
not have significant long-term changes in intelligence
quotient, daily living skills, or self-reported quality of life
indicators (26, 31). Future studies including the use of
formal neurocognitive testing are warranted and ongoing.
Notably, delaying RT until disease progression resulted
in worse toxicity profiles, rather than less treatment-related
toxicity as intended. Progressive cyst growth severely
affected both vision and rates of hypothalamic obesity, and
reserving RT until disease progression negatively affected
endocrine function as well, resulting in higher rates of
panhypopituitarism. Therefore, on the basis of these ob-
servations and previous reports, we recommend RT not be
withheld in the adjuvant setting.
Specific indicators of PBT clinical benefit have not yet
been identified. In this analysis we observed no difference in
late toxicity between patients treated with PBT compared
with IMRT. However, given the proximity of craniophar-
yngiomas to many critical structures that cannot be avoided,
the value of PBT for this disease is in minimizing the inte-
gral dose associated with IMRT to brain and vasculature
(22); more sensitive measures of benefit need to be devel-
oped through prospective data collection and formal neuro-
cognitive testing.
This study did have limitations. We attempted to over-
come the limitations of small sample sizes associated with
a rare pediatric disease by performing a comparative, multi-
institutional analysis. Despite our having more patients than
most studies, the number of events was still limited, and
this study was subject to the biases inherent in any retro-
spective analysis. Moreover, the inclusion of more than
1 institution increased the sample size but also introduced
nonstandardized follow-up and complicated late effect
evaluations.
Several important differences exist between the 2 co-
horts that warrant mention: the treatment decade, length of
follow-up, and use of surveillance imaging during RT.
Surveillance imaging was not regularly incorporated into
clinical practice until 2006, which coincided with the
initiation of PBT treatments. Although these imbalances do
not seem to have influenced outcomes, they warrant
consideration when interpreting the results.
For future studies, standardizing definitions of recur-
rence and collecting prospective quality of life and neuro-
cognitive metrics would certainly improve meaningful
follow-up for children with craniopharyngioma.
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Current treatments for craniopharyngiomas offer excellent
survival and control rates but can nevertheless have sig-
nificant morbidity. Uniform classifications of disease pro-
gression among studies is important to facilitate
comparisons between nodular and cyst control rates. We
found that PBT and IMRT produced equivalent outcomes
related to survival and solid and cystic disease control. Cyst
growth is common during and after RT and should be
accounted for in treatment planning and follow-up; late cyst
growth significantly influences morbidity. Delaying RT
until disease progression may worsen visual and endocrine
function. Prospective quality-of-life and neurocognitive
studies are needed to better define late toxicity and identify
clinically meaningful quality indicators.
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